|
US5663060A
(en)
*
|
1992-04-07 |
1997-09-02 |
Emory University |
Hybrid human/animal factor VIII
|
|
US5364771A
(en)
*
|
1992-04-07 |
1994-11-15 |
Emory University |
Hybrid human/porcine factor VIII
|
|
US5859204A
(en)
*
|
1992-04-07 |
1999-01-12 |
Emory University |
Modified factor VIII
|
|
US5888974A
(en)
*
|
1992-04-07 |
1999-03-30 |
Emory University |
Hybrid human/animal factor VIII
|
|
US5744446A
(en)
*
|
1992-04-07 |
1998-04-28 |
Emory University |
Hybrid human/animal factor VIII
|
|
US6376463B1
(en)
*
|
1992-04-07 |
2002-04-23 |
Emory University |
Modified factor VIII
|
|
US6180371B1
(en)
|
1996-06-26 |
2001-01-30 |
Emory University |
Modified factor VIII
|
|
SE504074C2
(sv)
*
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
US5910481A
(en)
*
|
1995-11-13 |
1999-06-08 |
Immuno Ag |
Hybrid proteins with modified activity
|
|
DE19613620C2
(de)
*
|
1996-04-04 |
1998-04-16 |
Steag Micro Tech Gmbh |
Verfahren und Vorrichtung zum Trocknen von Substraten
|
|
CA2252896C
(en)
*
|
1996-04-24 |
2009-03-10 |
The Regents Of The University Of Michigan |
Inactivation resistant factor viii
|
|
US20040092442A1
(en)
*
|
1996-04-24 |
2004-05-13 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US8183344B2
(en)
*
|
1996-04-24 |
2012-05-22 |
University Of Michigan |
Inactivation resistant factor VIII
|
|
US6458563B1
(en)
*
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
US7560107B2
(en)
*
|
1996-06-26 |
2009-07-14 |
Emory University |
Modified factor VIII
|
|
US6200560B1
(en)
*
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
|
WO2000032750A1
(en)
|
1998-11-24 |
2000-06-08 |
Regents Of The University Of Minnesota |
Transgenic circulating endothelial cells
|
|
EP1351986A2
(en)
|
2001-01-12 |
2003-10-15 |
The American National Red Cross |
Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
|
|
AU2002327430A1
(en)
*
|
2001-08-08 |
2003-02-24 |
Genzyme Corporation |
Methods for treating diabetes and other blood sugar disorders
|
|
US20040143104A1
(en)
*
|
2001-08-08 |
2004-07-22 |
Wadsworth Samuel C. |
Methods of treating diabetes and other blood sugar disorders
|
|
ES2333598T5
(es)
*
|
2003-05-06 |
2013-09-04 |
Biogen Idec Hemophilia Inc |
Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
|
|
HUE054805T2
(hu)
|
2003-09-30 |
2021-09-28 |
Univ Pennsylvania |
Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik
|
|
WO2005046583A2
(en)
*
|
2003-10-30 |
2005-05-26 |
Emory University |
Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
|
|
US7211559B2
(en)
|
2003-10-31 |
2007-05-01 |
University Of Maryland, Baltimore |
Factor VIII compositions and methods
|
|
US20050107318A1
(en)
*
|
2003-11-17 |
2005-05-19 |
Samuel Wadsworth |
Methods of treating diabetes and other blood sugar disorders
|
|
SI1750733T1
(sl)
*
|
2004-05-03 |
2014-03-31 |
Emory University |
POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
|
|
EP3085389A1
(en)
|
2005-04-07 |
2016-10-26 |
The Trustees Of The University Of Pennsylvania |
Method of increasing the function of an aav vector
|
|
CA2656558A1
(en)
*
|
2006-06-30 |
2008-01-10 |
The Regents Of The University Of Michigan |
Method of producing factor viii proteins by recombinant methods
|
|
JP5997443B2
(ja)
*
|
2008-05-16 |
2016-09-28 |
バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC |
標的化凝固因子およびそれを使用する方法
|
|
CN102741275B
(zh)
|
2009-08-24 |
2016-08-03 |
阿穆尼克斯运营公司 |
凝血因子ix组合物及其制备和使用方法
|
|
WO2011069164A2
(en)
|
2009-12-06 |
2011-06-09 |
Biogen Idec Ma Inc. |
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
|
|
KR20130040844A
(ko)
|
2010-03-29 |
2013-04-24 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
약학적으로 유발된 전이유전자 제거 시스템
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
EP3508573A1
(en)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
|
SG10201509149VA
(en)
|
2010-11-05 |
2015-12-30 |
Baxter Int |
A new variant of antihemophilic factor viii having increased specific activity
|
|
SG10202007803QA
(en)
|
2011-02-17 |
2020-09-29 |
Univ Pennsylvania |
Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
|
|
CA2838833A1
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
AU2012282875B2
(en)
|
2011-07-08 |
2016-04-21 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
|
|
WO2013016454A1
(en)
|
2011-07-25 |
2013-01-31 |
Biogen Idec Hemophilia Inc. |
Assays to monitor bleeding disorders
|
|
EP2804623B1
(en)
|
2012-01-12 |
2019-08-07 |
Bioverativ Therapeutics Inc. |
Chimeric factor viii polypeptides and uses thereof
|
|
SMT201800586T1
(it)
|
2012-01-12 |
2019-01-11 |
Bioverativ Therapeutics Inc |
Riduzione dell'immunogenicita' contro il fattore viii negli individui che si sottopongono alla terapia con fattore viii
|
|
LT3564260T
(lt)
|
2012-02-15 |
2023-01-10 |
Bioverativ Therapeutics Inc. |
Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
|
|
EP2822577B1
(en)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
|
CN110054699A
(zh)
|
2012-07-11 |
2019-07-26 |
比奥贝拉蒂治疗公司 |
具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
|
|
US10001495B2
(en)
|
2012-07-25 |
2018-06-19 |
Bioverativ Therapeutics Inc. |
Blood factor monitoring assay and uses thereof
|
|
US10391152B2
(en)
|
2012-10-18 |
2019-08-27 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
EP3446700A1
(en)
|
2012-10-30 |
2019-02-27 |
Bioverativ Therapeutics Inc. |
Methods of using fviii polypeptide
|
|
ES2926798T3
(es)
|
2013-03-15 |
2022-10-28 |
Bioverativ Therapeutics Inc |
Formulaciones de polipéptido de factor VIII
|
|
WO2015012924A2
(en)
|
2013-04-29 |
2015-01-29 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
|
|
MX2015016567A
(es)
|
2013-06-28 |
2016-03-31 |
Biogen Ma Inc |
Enlazador escindible por trombina con xten y usos del mismo.
|
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
|
TWI667255B
(zh)
|
2013-08-14 |
2019-08-01 |
美商生物化學醫療公司 |
因子viii-xten融合物及其用途
|
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
|
EP3082848B1
(en)
|
2013-12-06 |
2023-10-18 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
|
SG11201605242YA
(en)
|
2014-01-10 |
2016-07-28 |
Biogen Ma Inc |
Factor viii chimeric proteins and uses thereof
|
|
EP3283126B1
(en)
|
2015-04-16 |
2019-11-06 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
|
IL257231B
(en)
|
2015-08-03 |
2022-09-01 |
Bioverativ Therapeutics Inc |
Factor ix fusion proteins and methods of making and using same
|
|
WO2017103822A1
(en)
|
2015-12-16 |
2017-06-22 |
The New Zealand Institute For Plant And Food Research Limited |
Compositions and methods for manipulating the development of plants
|
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
|
JP2019536794A
(ja)
|
2016-12-02 |
2019-12-19 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凝固因子に対する免疫寛容を誘導する方法
|
|
SI3793588T1
(sl)
|
2018-05-18 |
2025-07-31 |
Bioverativ Therapeutics Inc. |
Postopki zdravljenja hemofilije A
|
|
EP3870206A4
(en)
*
|
2018-10-23 |
2023-04-26 |
The Children's Hospital Of Philadelphia |
COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION
|
|
KR20230042754A
(ko)
|
2020-08-07 |
2023-03-29 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
소포 표적화 단백질 및 이의 용도
|
|
WO2024077110A2
(en)
|
2022-10-05 |
2024-04-11 |
Roger Paul Hellens |
Uorf::reporter gene fusions to select sequence changes to gene edit into uorfs to regulate ascorbate genes
|